Short Interest in Equillium, Inc. (NASDAQ:EQ) Declines By 45.9%

Equillium, Inc. (NASDAQ:EQ) saw a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 363,900 shares, a decrease of 45.9% from the February 13th total of 672,300 shares. Based on an average trading volume of 770,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 2.1% of the shares of the stock are short sold.

Equillium Stock Down 3.2 %

NASDAQ:EQ traded down $0.03 during trading hours on Friday, reaching $0.75. 111,892 shares of the company’s stock were exchanged, compared to its average volume of 365,234. The company has a market capitalization of $26.75 million, a P/E ratio of -5.39 and a beta of 1.87. Equillium has a 12 month low of $0.49 and a 12 month high of $2.99. The business’s 50-day simple moving average is $0.76 and its two-hundred day simple moving average is $0.81.

Hedge Funds Weigh In On Equillium

An institutional investor recently raised its position in Equillium stock. DCF Advisers LLC lifted its position in Equillium, Inc. (NASDAQ:EQ) by 91.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 62,947 shares of the company’s stock after acquiring an additional 29,985 shares during the quarter. DCF Advisers LLC owned approximately 0.18% of Equillium worth $47,000 as of its most recent filing with the SEC. 27.05% of the stock is currently owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.